CoChat

Biological Effects of Quinolones: A Family of Broad-Spectrum Antimicrobial Agents

Open access
Millanao, Ana R., Mora, Aracely Y., Villagra, Nicolás A., Bucarey, Sergio A., Hidalgo, Alejandro A. · 2021 · Molecules
Cited by 213

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Broad antibacterial spectrum, high oral bioavailability and excellent tissue penetration combined with safety and few, yet rare, unwanted effects, have made the quinolones class of antimicrobials one of the most used in inpatients and outpatients. Initially discovered during the search for improved chloroquine-derivative molecules with increased anti-malarial activity, today the quinolones, intended as antimicrobials, comprehend four generations that progressively have been extending antimicrobial spectrum and clinical use. The quinolone class of antimicrobials exerts its antimicrobial actions through inhibiting DNA gyrase and Topoisomerase IV that in turn inhibits synthesis of DNA and RNA. Good distribution through different tissues and organs to treat Gram-positive and Gram-negative bacteria have made quinolones a good choice to treat disease in both humans and animals. The extensive use of quinolones, in both human health and in the veterinary field, has induced a rise of resistance and menace with leaving the quinolones family ineffective to treat infections. This review revises the evolution of quinolones structures, biological activity, and the clinical importance of this evolving family. Next, updated information regarding the mechanism of antimicrobial activity is revised. The veterinary use of quinolones in animal productions is also considered for its environmental role in spreading resistance. Finally, considerations for the use of quinolones in human and veterinary medicine are discussed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/molecules26237153

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 305

  1. Price, 1949, Alkaloids of the Australian Rutaceae: Melicope fareana. I. Isolation of the Constituent Alkaloids, Aust. J. Chem., 2, 249, 10.1071/CH9490249 · doi:10.1071/ch9490249
  2. Drummond, 1949, Alkaloids of the Australian Rutaceae: Acronychia baueri. III. The Structure of Acronycine, Aust. J. Chem., 2, 630, 10.1071/CH9490630 · doi:10.1071/ch9490630
  3. Crow, 1949, Alkaloids of the Australian Rutaceae: Melicope fareana. V. The Structure of the Alkaloids, Aust. J. Chem., 2, 282, 10.1071/CH9490282 · doi:10.1071/ch9490282
  4. Bisacchi, 2015, Origins of the Quinolone Class of Antibacterials: An Expanded “Discovery Story”, J. Med. Chem., 58, 4874, 10.1021/jm501881c · DOI · Paper page
  5. Mitscher, 2005, Bacterial Topoisomerase Inhibitors: Quinolone and Pyridone Antibacterial Agents, Chem. Rev., 105, 559, 10.1021/cr030101q · DOI · Paper page
  6. Redgrave, 2014, Fluoroquinolone Resistance: Mechanisms, Impact on Bacteria, and Role in Evolutionary Success, Trends Microbiol., 22, 438, 10.1016/j.tim.2014.04.007 · DOI · Paper page
  7. Andersson, 2003, Development of the Quinolones, J. Antimicrob. Chemother., 51, 1, 10.1093/jac/dkg212 · DOI
  8. Mandell, 2002, Safety of Fluoroquinolones: An Update, Can. J. Infect. Dis., 13, 54
  9. Nagaoka, S. (2019). Drug Discovery in Japan: Investigating the Sources of Innovation, Springer. · doi:10.1007/978-981-13-8906-1
  10. Pavithra, 2010, PK-PD Modelling of Norfloxacin after Oral Administration in Rabbits, Vet. World, 3, 546
  11. Appelbaum, 1999, Quinolone Activity Against Anaerobes, Drugs, 58, 60, 10.2165/00003495-199958002-00012 · DOI
  12. Prabhala, 1984, In Vitro Susceptibility of Anaerobic Bacteria to Ciprofloxacin (Bay o 9867), Antimicrob. Agents Chemother., 26, 785, 10.1128/AAC.26.5.785 · doi:10.1128/aac.26.5.785
  13. Goldstein, 1992, Comparative Activity of Ciprofloxacin, Ofloxacin, Sparfloxacin, Temafloxacin, CI-960, CI-990, and WIN 57273 against Anaerobic Bacteria, Antimicrob. Agents Chemother., 36, 1158, 10.1128/AAC.36.5.1158 · doi:10.1128/aac.36.5.1158
  14. Naeem, A., Badshah, S.L., Muska, M., Ahmad, N., and Khan, K. (2016). The Current Case of Quinolones: Synthetic Approaches and Antibacterial Activity. Molecules, 21. · DOI · Paper page
  15. King, 2000, New Classification and Update on the Quinolone Antibiotics, Am. Fam. Physician, 61, 2741
  16. Wexler, 1994, In Vitro Activity of DU-6859a against Anaerobic Bacteria, Antimicrob. Agents Chemother., 38, 2504, 10.1128/AAC.38.10.2504 · doi:10.1128/aac.38.10.2504
  17. Balwan, 2015, Clinafloxacin for Treatment of Burkholderia Cenocepacia Infection in a Cystic Fibrosis Patient, Antimicrob. Agents Chemother., 60, 1, 10.1128/AAC.01428-15 · DOI
  18. Lauderdale, 2010, Comparative In Vitro Activities of Nemonoxacin (TG-873870), a Novel Nonfluorinated Quinolone, and Other Quinolones against Clinical Isolates, Antimicrob. Agents Chemother., 54, 1338, 10.1128/AAC.01197-09 · doi:10.1128/aac.01197-09
  19. Stubbings, 2009, New Antibiotics for Antibiotic-Resistant Bacteria, F1000 Biol. Rep., 1, 40, 10.3410/B1-40 · doi:10.3410/b1-40
  20. Roychoudhury, 2001, Activity of Non-Fluorinated Quinolones (NFQs) against Quinolone-Resistant Escherichia coli and Streptococcus pneumoniae, J. Antimicrob. Chemother., 48, 29, 10.1093/jac/48.1.29 · DOI
  21. Adam, 2009, In Vitro Activity of Nemonoxacin, a Novel Nonfluorinated Quinolone, against 2440 Clinical Isolates, Antimicrob. Agents Chemother., 53, 4915, 10.1128/AAC.00078-09 · doi:10.1128/aac.00078-09
  22. Qin, 2014, Review of Nemonoxacin with Special Focus on Clinical Development, Drug Des. Dev. Ther., 8, 765
  23. Borges, 2013, Antibacterial Activity and Mode of Action of Ferulic and Gallic Acids Against Pathogenic Bacteria, Microb. Drug Resist., 19, 256, 10.1089/mdr.2012.0244 · DOI · Paper page
  24. Ibitoye, 2019, Ferulic Acid Potentiates the Antibacterial Activity of Quinolone-Based Antibiotics against Acinetobacter baumannii, Microb. Pathog., 126, 393, 10.1016/j.micpath.2018.11.033 · DOI
  25. Courtney, 2017, Potentiating Antibiotics in Drug-Resistant Clinical Isolates via Stimuli-Activated Superoxide Generation, Sci. Adv., 3, e1701776, 10.1126/sciadv.1701776 · DOI
  26. Neu, 1991, Synergy and Antagonism of Combinations with Quinolones, Eur. J. Clin. Microbiol. Infect. Dis., 10, 255, 10.1007/BF01966998 · doi:10.1007/bf01966998
  27. Tintino, S.R., de Souza, V.C.A., da Silva, J.M.A., Oliveira-Tintino, C.D.d.M., Pereira, P.S., Leal-Balbino, T.C., Pereira-Neves, A., Siqueira-Junior, J.P., da Costa, J.G.M., and Rodrigues, F.F.G. (2020). Effect of Vitamin K3 Inhibiting the Function of NorA Efflux Pump and Its Gene Expression on Staphylococcus aureus. Membranes, 10. · DOI
  28. Lim, 2019, Identification of a Potent Small-Molecule Inhibitor of Bacterial DNA Repair That Potentiates Quinolone Antibiotic Activity in Methicillin-Resistant Staphylococcus aureus, Bioorgan. Med. Chem., 27, 114962, 10.1016/j.bmc.2019.06.025 · DOI
  29. Wilkinson, 2016, Structural Basis for the Inhibition of RecBCD by Gam and Its Synergistic Antibacterial Effect with Quinolones, eLife, 5, e22963, 10.7554/eLife.22963 · DOI
  30. Liu, 2009, Synergistic Effect of Kaempferol Glycosides Purified from Laurus Nobilis and Fluoroquinolones on Methicillin-Resistant Staphylococcus aureus, Biol. Pharm. Bull., 32, 489, 10.1248/bpb.32.489 · DOI
  31. Cannalire, 2017, Natural Isoflavone Biochanin A as a Template for the Design of New and Potent 3-Phenylquinolone Efflux Inhibitors against Mycobacterium avium, Eur. J. Med. Chem., 140, 321, 10.1016/j.ejmech.2017.09.014 · DOI
  32. Duan, 2016, L-Serine Potentiates Fluoroquinolone Activity against Escherichia Coli by Enhancing Endogenous Reactive Oxygen Species Production, J. Antimicrob. Chemother., 71, 2192, 10.1093/jac/dkw114 · DOI
  33. Wang, 2020, Palmatine Is a Plasmid-Mediated Quinolone Resistance (PMQR) Inhibitor That Restores the Activity of Ciprofloxacin Against QnrS and AAC(6ʹ)-Ib-Cr-Producing Escherichia coli, Infect. Drug Resist., 13, 749, 10.2147/IDR.S242304 · DOI
  34. Bradfute, S.B., Ye, C., Clarke, E.C., Kumar, S., Timmins, G.S., and Deretic, V. (2020). Ambroxol and Ciprofloxacin Show Activity Against SARS-CoV2 in Vero E6 Cells at Clinically-Relevant Concentrations. bioRxiv. · DOI
  35. Wei, 2017, Activity of Levofloxacin in Combination with Colistin against Acinetobacter baumannii: In Vitro and in a Galleria mellonella Model, J. Microbiol. Immunol. Infect., 50, 821, 10.1016/j.jmii.2015.10.010 · doi:10.1016/j.jmii.2015.10.010
  36. Gorityala, 2015, Adjuvants Based on Hybrid Antibiotics Overcome Resistance in Pseudomonas aeruginosa and Enhance Fluoroquinolone Efficacy, Angew. Chem. Int. Ed. Engl., 55, 555, 10.1002/anie.201508330 · DOI
  37. Gorityala, 2016, Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux, J. Med. Chem., 59, 8441, 10.1021/acs.jmedchem.6b00867 · DOI
  38. Domalaon, 2018, Antibiotic Hybrids: The Next Generation of Agents and Adjuvants against Gram-Negative Pathogens?, Clin. Microbiol. Rev., 31, e00077-17, 10.1128/CMR.00077-17 · DOI · Paper page
  39. Park, 2002, Physicochemical Properties of Quinolone Antibiotics in Various Environments, Eur. J. Med. Chem., 37, 443, 10.1016/S0223-5234(02)01361-2 · DOI · Paper page
  40. Ross, 1992, Physicochemical Properties of the Fluoroquinolone Antimicrobials. II. Acid Ionization Constants and Their Relationship to Structure, Int. J. Pharm., 83, 267, 10.1016/0378-5173(82)90032-1 · doi:10.1016/0378-5173(82)90032-1
  41. Cramariuc, 2012, Mechanism for Translocation of Fluoroquinolones across Lipid Membranes, Biochim. Biophys. Acta BBA Biomembr., 1818, 2563, 10.1016/j.bbamem.2012.05.027 · DOI
  42. 2015, Delafloxacin, a Non-Zwitterionic Fluoroquinolone in Phase III of Clinical Development: Evaluation of Its Pharmacology, Pharmacokinetics, Pharmacodynamics and Clinical Efficacy, Future Microbiol., 10, 1111, 10.2217/fmb.15.39 · doi:10.2217/fmb.15.39
  43. Lodise, 2018, Safety of Delafloxacin: Focus on Adverse Events of Special Interest, Open Forum Infect. Dis., 5, ofy220, 10.1093/ofid/ofy220 · DOI
  44. Rusu, A., Lungu, I.-A., Moldovan, O.-L., Tanase, C., and Hancu, G. (2021). Structural Characterization of the Millennial Antibacterial (Fluoro)Quinolones—Shaping the Fifth Generation. Pharmaceutics, 13. · DOI
  45. Biernacka, 2014, Experimental and Theoretical Studies on the Molecular Properties of Ciprofloxacin, Norfloxacin, Pefloxacin, Sparfloxacin, and Gatifloxacin in Determining Bioavailability, J. Biol. Phys., 40, 335, 10.1007/s10867-014-9354-z · DOI
  46. Biernacka, 2014, Physicochemical Properties of Lomefloxacin, Levofloxacin, and Moxifloxacin Relevant to the Biopharmaceutics Classification System, Acta Chim. Slov., 61, 827
  47. Uivarosi, 2013, Metal Complexes of Quinolone Antibiotics and Their Applications: An Update, Molecules, 18, 11153, 10.3390/molecules180911153 · DOI
  48. Ross, 1993, Physicochemical Properties of the Fluoroquinolone Antimicrobials V. Effect of Fluoroquinolone Structure and PH on the Complexation of Various Fluoroquinolones with Magnesium and Calcium Ions, Int. J. Pharm., 93, 121, 10.1016/0378-5173(93)90170-K · doi:10.1016/0378-5173(93)90170-k
  49. Pitman, S.K., Hoang, U.T.P., Wi, C.H., Alsheikh, M., Hiner, D.A., and Percival, K.M. (2019). Revisiting Oral Fluoroquinolone and Multivalent Cation Drug-Drug Interactions: Are They Still Relevant?. Antibiotics, 8. · doi:10.3390/antibiotics8030108
  50. Stass, 2001, Effects of Iron Supplements on the Oral Bioavailability of Moxifloxacin, a Novel 8-Methoxyfluoroquinolone, in Humans, Clin. Pharm., 40, 57, 10.2165/00003088-200140001-00008 · doi:10.2165/00003088-200140001-00008
  51. Djurdjevic, 2014, The Effect of Some Fluoroquinolone Family Members on Biospeciation of Copper(II), Nickel(II) and Zinc(II) Ions in Human Plasma, Molecules, 19, 12194, 10.3390/molecules190812194 · DOI
  52. Wang, 2020, Dynamic Interaction of Fluoroquinolones with Magnesium Ions Monitored Using Bacterial Outer Membrane Nanopores, Chem. Sci., 11, 10344, 10.1039/D0SC03486J · DOI
  53. Valisena, 1990, Relevance of Ionic Effects on Norfloxacin Uptake by Escherichia coli, Biochem. Pharmacol., 40, 431, 10.1016/0006-2952(90)90540-2 · doi:10.1016/0006-2952(90)90540-2
  54. Mortimer, 1991, A comparison of methods used for measuring the accumulation of quinolones by Enterobacteriaceae, Pseudomonas aeruginosa and Staphylococcus aureus, J. Antimicrob. Chemother., 28, 639, 10.1093/jac/28.5.639 · doi:10.1093/jac/28.5.639
  55. Furet, 1992, Transport of Pefloxacin across the Bacterial Cytoplasmic Membrane in Quinolone-Susceptible Staphylococcus aureus, Antimicrob. Agents Chemother., 36, 2506, 10.1128/AAC.36.11.2506 · doi:10.1128/aac.36.11.2506
  56. Ross, 1992, Physicochemical Properties of the Fluoroquinolone Antimicrobials. III. 1-Octanol/Water Partition Coefficients and Their Relationships to Structure, Int. J. Pharm., 88, 379, 10.1016/0378-5173(92)90336-Z · doi:10.1016/0378-5173(92)90336-z
  57. Ferreira, M., Bessa, L.J., Sousa, C.F., Eaton, P., Bongiorno, D., Stefani, S., Campanile, F., and Gameiro, P. (2020). Fluoroquinolone Metalloantibiotics: A Promising Approach against Methicillin-Resistant Staphylococcus aureus. Int. J. Environ. Res. Public Health, 17. · DOI
  58. Feio, 2014, Fluoroquinolone–Metal Complexes: A Route to Counteract Bacterial Resistance?, J. Inorg. Biochem., 138, 129, 10.1016/j.jinorgbio.2014.05.007 · DOI
  59. Yang, S., Tian, M., Yuan, L., Deng, H., Wang, L., Li, A., Hou, Z., Li, Y., and Zhang, Y. (2020, September 25). Analysis of E. rutaecarpa Alkaloids Constituents In Vitro and In Vivo by UPLC-Q-TOF-MS Combined with Diagnostic Fragment. Available online: https://www.hindawi.com/journals/jamc/2016/4218967/. · doi:10.1155/2016/4218967
  60. Heeb, 2011, Quinolones: From Antibiotics to Autoinducers, FEMS Microbiol. Rev., 35, 247, 10.1111/j.1574-6976.2010.00247.x · DOI · Paper page
  61. Dekker, 1998, New Quinolone Compounds from Pseudonocardia Sp. with Selective and Potent Anti-Helicobacter pylori Activity: Taxonomy of Producing Strain, Fermentation, Isolation, Structural Elucidation and Biological Activities, J. Antibiot., 51, 145, 10.7164/antibiotics.51.145 · DOI
  62. Geddis, 2018, Synthesis and Biological Evaluation of 1,2-Disubstituted 4-Quinolone Analogues of Pseudonocardia Sp. Natural Products, Beilstein J. Org. Chem., 14, 2680, 10.3762/bjoc.14.245 · doi:10.3762/bjoc.14.245
  63. Jucker, E. (1977). Development of antibacterial agents of the nalidixic acid type. Progress in Drug Research/Fortschritte der Arzneimittelforschung/Progrès des Rechersches Pharmaceutiques, Birkhäuser. · doi:10.1007/978-3-0348-7098-6
  64. Schaumann, 2006, Activities of Quinolones Against Obligately Anaerobic Bacteria, Anti Infect. Agents Med. Chem., 6, 49, 10.2174/187152107779314179 · doi:10.2174/187152107779314179
  65. Bryskier, A. (2005). Antimicrobial Agents: Antibacterials and Antifungals, ASM Press. · DOI · Paper page
  66. Domagala, 1994, Structure-Activity and Structure-Side-Effect Relationships for the Quinolone Antibacterials, J. Antimicrob. Chemother., 33, 685, 10.1093/jac/33.4.685 · DOI · Paper page
  67. Takahashi, 2003, The history of the development and changes of quinolone antibacterial agents, Yakushigaku Zasshi, 38, 161
  68. Emmerson, 2003, The Quinolones: Decades of Development and Use, J. Antimicrob. Chemother., 51, 13, 10.1093/jac/dkg208 · DOI · Paper page
  69. Rohlfing, 1976, Bioevaluation of the Antibacterial Flumequine for Urinary Tract Use, Antimicrob. Agents Chemother., 10, 20, 10.1128/AAC.10.1.20 · doi:10.1128/aac.10.1.20
  70. Wise, 1983, In Vitro Activity of Bay 09867, a New Quinoline Derivative, Compared with Those of Other Antimicrobial Agents, Antimicrob. Agents Chemother., 23, 559, 10.1128/AAC.23.4.559 · doi:10.1128/aac.23.4.559
  71. Chin, 1984, Ciprofloxacin, a Quinolone Carboxylic Acid Compound Active against Aerobic and Anaerobic Bacteria, Antimicrob. Agents Chemother., 25, 319, 10.1128/AAC.25.3.319 · doi:10.1128/aac.25.3.319
  72. Hoshino, 1989, Inhibitory Effects of Quinolones on DNA Gyrase of Escherichia coli and Topoisomerase II of Fetal Calf Thymus, Antimicrob. Agents Chemother., 33, 1816, 10.1128/AAC.33.10.1816 · DOI
  73. Shah, 2007, The Role of Fluorine in Medicinal Chemistry, J Enzym. Inhib. Med. Chem., 22, 527, 10.1080/14756360701425014 · DOI · Paper page
  74. Sato, 1982, In Vitro and in Vivo Activity of DL-8280, a New Oxazine Derivative, Antimicrob. Agents Chemother., 22, 548, 10.1128/AAC.22.4.548 · doi:10.1128/aac.22.4.548
  75. Woodcock, 1997, In Vitro Activity of BAY 12-8039, a New Fluoroquinolone, Antimicrob. Agents Chemother., 41, 101, 10.1128/AAC.41.1.101 · DOI · Paper page
  76. Lu, 2001, Enhancement of Fluoroquinolone Activity by C-8 Halogen and Methoxy Moieties: Action against a Gyrase Resistance Mutant of Mycobacterium smegmatis and a Gyrase-Topoisomerase IV Double Mutant of Staphylococcus aureus, Antimicrob. Agents Chemother., 45, 2703, 10.1128/AAC.45.10.2703-2709.2001 · doi:10.1128/aac.45.10.2703-2709.2001
  77. Ruiz, 2019, Transferable Mechanisms of Quinolone Resistance from 1998 Onward, Clin. Microbiol. Rev., 32, e00007-19, 10.1128/CMR.00007-19 · DOI
  78. Klomp, F., Wenzel, C., Drozdzik, M., and Oswald, S. (2020). Drug–Drug Interactions Involving Intestinal and Hepatic CYP1A Enzymes. Pharmaceutics, 12. · DOI
  79. Bridle, 2017, Computational Study of Fluoroquinolone Binding to Mg(H2O)N2+ and Its Applicability to Future Drug Design, Int. J. Quantum Chem., 117, e25428, 10.1002/qua.25428 · doi:10.1002/qua.25428
  80. Panda, 2015, Novel Antibacterial Active Quinolone–Fluoroquinolone Conjugates and 2D-QSAR Studies, Bioorgan. Med. Chem. Lett., 25, 3816, 10.1016/j.bmcl.2015.07.077 · DOI
  81. Hou, Y., Zhao, Y., and Li, Y. (2020). Environmentally Friendly Fluoroquinolone Derivatives with Lower Plasma Protein Binding Rate Designed Using 3D-QSAR, Molecular Docking and Molecular Dynamics Simulation. Int. J. Environ. Res. Public Health, 17. · doi:10.3390/ijerph17186626
  82. Zhao, 2019, Combined QSAR/QSPR and Molecular Docking Study on Fluoroquinolones to Reduce Biological Enrichment, Comput. Biol. Chem., 79, 177, 10.1016/j.compbiolchem.2019.02.008 · doi:10.1016/j.compbiolchem.2019.02.008
  83. (2021, October 28). Molecular Design of Lower Photodegradation Fluoroquinolone Antibiotics and Their Photolysis Paths Inference. Available online: http://www.cjcu.jlu.edu.cn/EN/10.7503/cjcu20180475. · doi:10.7503/cjcu20180475
  84. Sass, 2017, Computer-Aided Drug Design Methods, Antibiotics, Volume 1520, 85, 10.1007/978-1-4939-6634-9_5 · DOI · Paper page
  85. Sarma, 1989, Norfloxacin: A New Drug in the Treatment of Falciparum Malaria, Ann. Intern. Med., 111, 336, 10.7326/0003-4819-111-4-336 · doi:10.7326/0003-4819-111-4-336
  86. Tripathi, 1993, Curative Efficacy of Norfloxacin in Falciparum Malaria, Indian J. Med. Res., 97, 176
  87. Dalhoff, 2015, Antiviral, Antifungal, and Antiparasitic Activities of Fluoroquinolones Optimized for Treatment of Bacterial Infections: A Puzzling Paradox or a Logical Consequence of Their Mode of Action?, Eur. J. Clin. Microbiol. Infect. Dis., 34, 661, 10.1007/s10096-014-2296-3 · doi:10.1007/s10096-014-2296-3
  88. Ridley, 1996, 4-Aminoquinoline Analogs of Chloroquine with Shortened Side Chains Retain Activity against Chloroquine-Resistant Plasmodium falciparum, Antimicrob. Agents Chemother., 40, 1846, 10.1128/AAC.40.8.1846 · doi:10.1128/aac.40.8.1846
  89. Garcia, 2010, Malaria, Clin. Lab. Med., 30, 93, 10.1016/j.cll.2009.10.001 · DOI · Paper page
  90. Cross, 2010, Endochin Optimization: Structure-Activity and Structure-Property Relationship Studies of 3-Substituted 2-Methyl-4(1H)-Quinolones with Antimalarial Activity, J. Med. Chem., 53, 7076, 10.1021/jm1007903 · DOI
  91. Kurasawa, 2012, Quinolone Analogs 11: Synthesis of Novel 4-Quinolone-3-Carbohydrazide Derivatives with Antimalarial Activity, J. Heterocycl. Chem., 49, 288, 10.1002/jhet.774 · doi:10.1002/jhet.774
  92. Martins, 2016, Norfloxacin and N-Donor Mixed-Ligand Copper(II) Complexes: Synthesis, Albumin Interaction, and Anti-Trypanosoma cruzi Activity, Bioinorg. Chem. Appl., 2016, 5027404, 10.1155/2016/5027404 · doi:10.1155/2016/5027404
  93. Hiltensperger, 2016, Quinolone Amides as Antitrypanosomal Lead Compounds with In Vivo Activity, Antimicrob. Agents Chemother., 60, 4442, 10.1128/AAC.01757-15 · DOI
  94. Wang, 2012, Design, Synthesis and Evaluation of Clinafloxacin Triazole Hybrids as a New Type of Antibacterial and Antifungal Agents, Bioorgan. Med. Chem. Lett., 22, 5363, 10.1016/j.bmcl.2012.07.064 · DOI
  95. Mohamed, 2011, Ligational Behaviour of Lomefloxacin Drug towards Cr(III), Mn(II), Fe(III), Co(II), Ni(II), Cu(II), Zn(II), Th(IV) and UO2(VI) Ions: Synthesis, Structural Characterization and Biological Activity Studies, Spectrochim. Acta Part A Mol. Biomol. Spectrosc., 82, 8, 10.1016/j.saa.2011.05.089 · DOI
  96. Sultana, 2010, Synthesis, Characterization, Antibacterial, Antifungal and Immunomodulating Activities of Gatifloxacin–Metal Complexes, J. Mol. Struct., 969, 17, 10.1016/j.molstruc.2010.01.036 · doi:10.1016/j.molstruc.2010.01.036
  97. Debnath, 2015, Metal Complex of the First-Generation Quinolone Antimicrobial Drug Nalidixic Acid: Structure and Its Biological Evaluation, Appl Biochem Biotechnol, 175, 2659, 10.1007/s12010-014-1450-9 · doi:10.1007/s12010-014-1450-9
  98. Khamkhenshorngphanuch, T., Kulkraisri, K., Janjamratsaeng, A., Plabutong, N., Thammahong, A., Manadee, K., Na Pombejra, S., and Khotavivattana, T. (2020). Synthesis and Antimicrobial Activity of Novel 4-Hydroxy-2-Quinolone Analogs. Molecules, 25. · doi:10.3390/molecules25133059
  99. Xi, 2007, Helicases as Antiviral and Anticancer Drug Targets, Curr. Med. Chem., 14, 883, 10.2174/092986707780362998 · doi:10.2174/092986707780362998
  100. Portolani, 1988, Suppression of BK Virus Replication and Cytopathic Effect by Inhibitors of Prokaryotic DNA Gyrase, Antivir. Res., 9, 205, 10.1016/0166-3542(88)90004-6 · doi:10.1016/0166-3542(88)90004-6
  101. Koukoulaki, 2008, Impact of Prophylactic Administration of Ciprofloxacin on BK Polyoma Virus Replication, Transpl. Infect. Dis., 10, 449, 10.1111/j.1399-3062.2008.00334.x · doi:10.1111/j.1399-3062.2008.00334.x
  102. Ali, 2007, Inhibition of Simian Virus 40 Large T Antigen Helicase Activity by Fluoroquinolones, Antivir. Ther., 12, 1, 10.1177/135965350701200104 · doi:10.1177/135965350701200104
  103. Khan, 2012, Fluoroquinolones Inhibit HCV by Targeting Its Helicase, Antivir. Ther., 17, 467, 10.3851/IMP1937 · DOI
  104. Habtemariam, 2020, Should We Try SARS-CoV-2 Helicase Inhibitors for COVID-19 Therapy?, Arch. Med Res., 51, 733, 10.1016/j.arcmed.2020.05.024 · doi:10.1016/j.arcmed.2020.05.024
  105. Marciniec, 2020, Ciprofloxacin and Moxifloxacin Could Interact with SARS-CoV-2 Protease: Preliminary in Silico Analysis, Pharm. Rep., 72, 1553, 10.1007/s43440-020-00169-0 · DOI
  106. Tauber, 2008, Immunomodulatory Properties of Antibiotics, Curr. Mol. Pharm., 1, 68, 10.2174/1874467210801010068 · DOI
  107. Dalhoff, 2003, Immunomodulatory Effects of Quinolones, Lancet Infect. Dis., 3, 359, 10.1016/S1473-3099(03)00658-3 · DOI · Paper page
  108. Ogino, 2009, In Vivo and in Vitro Effects of Fluoroquinolones on Lipopolysaccharide-Induced pro-Inflammatory Cytokine Production, J. Infect. Chemother., 15, 168, 10.1007/s10156-009-0680-1 · DOI
  109. Zhang, 2008, Besifloxacin, a Novel Fluoroquinolone Antimicrobial Agent, Exhibits Potent Inhibition of pro-Inflammatory Cytokines in Human THP-1 Monocytes, J. Antimicrob. Chemother., 61, 111, 10.1093/jac/dkm398 · DOI
  110. Zusso, 2019, Ciprofloxacin and Levofloxacin Attenuate Microglia Inflammatory Response via TLR4/NF-KB Pathway, J. Neuroinflamm., 16, 148, 10.1186/s12974-019-1538-9 · DOI · Paper page
  111. Araujo, 2002, Effect of Moxifloxacin on Secretion of Cytokines by Human Monocytes Stimulated with Lipopolysaccharide, Clin. Microbiol. Infect., 8, 26, 10.1046/j.1469-0691.2002.00374.x · DOI
  112. Shalit, 2006, Anti-Inflammatory Effects of Moxifloxacin on IL-8, IL-1beta and TNF-Alpha Secretion and NFkappaB and MAP-Kinase Activation in Human Monocytes Stimulated with Aspergillus fumigatus, J. Antimicrob. Chemother., 57, 230, 10.1093/jac/dki441 · DOI
  113. Fabian, 2006, Moxifloxacin Enhances Antiproliferative and Apoptotic Effects of Etoposide but Inhibits Its Proinflammatory Effects in THP-1 and Jurkat Cells, Br. J. Cancer, 95, 1038, 10.1038/sj.bjc.6603355 · doi:10.1038/sj.bjc.6603355
  114. Batalha, 2016, Quinolones in the Search for New Anticancer Agents, Curr. Pharm. Des., 22, 6009, 10.2174/1381612822666160715115025 · doi:10.2174/1381612822666160715115025
  115. Beberok, 2018, Ciprofloxacin Triggers the Apoptosis of Human Triple-Negative Breast Cancer MDA-MB-231 Cells via the P53/Bax/Bcl-2 Signaling Pathway, Int. J. Oncol., 52, 1727
  116. Beberok, 2018, Ciprofloxacin-Mediated Induction of S-Phase Cell Cycle Arrest and Apoptosis in COLO829 Melanoma Cells, Pharmacol. Rep., 70, 6, 10.1016/j.pharep.2017.07.007 · DOI
  117. Nishi, 2017, Enoxacin with UVA Irradiation Induces Apoptosis in the AsPC1 Human Pancreatic Cancer Cell Line Through ROS Generation, Anticancer Res., 37, 6211
  118. Beberok, 2018, GSH Depletion, Mitochondrial Membrane Breakdown, Caspase-3/7 Activation and DNA Fragmentation in U87MG Glioblastoma Cells: New Insight into the Mechanism of Cytotoxicity Induced by Fluoroquinolones, Eur. J. Pharmacol., 835, 94, 10.1016/j.ejphar.2018.08.002 · DOI
  119. Patitungkho, 2011, Synthesis, Characterization and Anti-Tumor Activity of Moxifloxacin-Copper Complexes against Breast Cancer Cell Lines, Bioorgan. Med. Chem. Lett., 21, 1802, 10.1016/j.bmcl.2011.01.061 · doi:10.1016/j.bmcl.2011.01.061
  120. Nakai, 2017, Photodynamically-Induced Apoptosis Due to Ultraviolet A in the Presence of Lomefloxacin in Human Promyelocytic Leukemia Cells, Anticancer Res., 37, 6407
  121. Yadav, 2019, Repositioning of Fluoroquinolones from Antibiotic to Anti-Cancer Agents: An Underestimated Truth, Biomed. Pharmacother., 111, 934, 10.1016/j.biopha.2018.12.119 · DOI · Paper page
  122. Berninger, 2018, Fluorine Walk: The Impact of Fluorine in Quinolone Amides on Their Activity against African Sleeping Sickness, Eur. J. Med. Chem., 152, 377, 10.1016/j.ejmech.2018.04.055 · DOI
  123. Kraus, 2010, Second Generation Analogues of the Cancer Drug Clinical Candidate Tipifarnib for Anti-Chagas Disease Drug Discovery, J. Med. Chem., 53, 3887, 10.1021/jm9013136 · doi:10.1021/jm9013136
  124. Xu, 2019, Fluoroquinolone-Isatin Hybrids and Their Biological Activities, Eur. J. Med. Chem., 162, 396, 10.1016/j.ejmech.2018.11.032 · DOI
  125. Kljun, 2011, Physicochemical Studies and Anticancer Potency of Ruthenium H6-p-Cymene Complexes Containing Antibacterial Quinolones, Organometallics, 30, 2506, 10.1021/om101180c · DOI
  126. Regmi, 2007, Lack of Inhibitory Effects of Several Fluoroquinolones on Cytochrome P-450 3A Activities at Clinical Dosage in Dogs, J. Vet. Pharm., 30, 37, 10.1111/j.1365-2885.2007.00810.x · doi:10.1111/j.1365-2885.2007.00810.x
  127. Zhang, 2015, Synthesis and Anticonvulsant Activity Evaluation of 4-Phenyl-[1,2,4]Triazolo[4,3-a]Quinazolin-5(4H)-One and Its Derivatives, Arch. Pharm., 348, 564, 10.1002/ardp.201500115 · doi:10.1002/ardp.201500115
  128. Ukrainets, 2007, 4-Hydroxy-2-Quinolones 121. Synthesis and Biological Properties of 1-Hydroxy-3-Oxo-5,6-Dihydro-3h-Pyrrolo[3,2,1-Ij]Quino-Line-2-Carboxylic Acid Alkylamides, Chem. Heterocycl. Compd., 43, 856, 10.1007/s10593-007-0136-4 · doi:10.1007/s10593-007-0136-4
  129. Michot, 2005, Quinolones in 2005: An Update, Clin. Microbiol. Infect., 11, 256, 10.1111/j.1469-0691.2005.01131.x · DOI · Paper page
  130. Goa, 1997, Sparfloxacin. A Review of Its Antibacterial Activity, Pharmacokinetic Properties, Clinical Efficacy and Tolerability in Lower Respiratory Tract Infections, Drugs, 53, 700, 10.2165/00003495-199753040-00010 · doi:10.2165/00003495-199753040-00010
  131. Oliphant, 2002, Quinolones: A Comprehensive Review, Am. Fam. Physician, 65, 455
  132. Nicolau, 1992, Ofloxacin vs. Ciprofloxacin: A Comparison, Connect. Med., 56, 261
  133. Bidell, 2016, Fluoroquinolone-Associated Tendinopathy: Does Levofloxacin Pose the Greatest Risk?, Pharmacotherapy, 36, 679, 10.1002/phar.1761 · doi:10.1002/phar.1761
  134. Rubinstein, 2001, History of Quinolones and Their Side Effects, Chemotherapy, 47, 3, 10.1159/000057838 · DOI
  135. Haria, 1997, Trovafloxacin, Drugs, 54, 435, 10.2165/00003495-199754030-00006 · doi:10.2165/00003495-199754030-00006
  136. Cunha, 2001, Antibiotic Side Effects, Med. Clin. N. Am., 85, 149, 10.1016/S0025-7125(05)70309-6 · DOI · Paper page
  137. Stewardson, 2015, SATURN WP1 and WP3 Study Groups. Collateral Damage from Oral Ciprofloxacin vs. Nitrofurantoin in Outpatients with Urinary Tract Infections: A Culture-Free Analysis of Gut Microbiota, Clin. Microbiol. Infect., 21, 344.e1, 10.1016/j.cmi.2014.11.016 · DOI
  138. Fox, 2017, A Seven-Day Course of Trimethoprim-Sulfamethoxazole May Be as Effective as a Seven-Day Course of Ciprofloxacin for the Treatment of Pyelonephritis, Am. J. Med., 130, 842, 10.1016/j.amjmed.2017.01.025 · DOI
  139. Lee, 2014, Comparative Effectiveness of Different Oral Antibiotics Regimens for Treatment of Urinary Tract Infection in Outpatients: An Analysis of National Representative Claims Database, Medicine, 93, e304, 10.1097/MD.0000000000000304 · DOI
  140. Hooper, 2000, New Uses for New and Old Quinolones and the Challenge of Resistance, Clin. Infect. Dis., 30, 243, 10.1086/313677 · DOI · Paper page
  141. Kreling, 2020, Campylobacter Sp.: Pathogenicity Factors and Prevention Methods—New Molecular Targets for Innovative Antivirulence Drugs?, Appl. Microbiol. Biotechnol., 104, 10409, 10.1007/s00253-020-10974-5 · DOI
  142. Berning, 2011, Should Quinolones Come First in Helicobacter Pylori Therapy?, Ther. Adv. Gastroenterol., 4, 103, 10.1177/1756283X10384171 · doi:10.1177/1756283x10384171
  143. Wentzell, 2000, The Complex of DNA Gyrase and Quinolone Drugs on DNA Forms a Barrier to the T7 DNA Polymerase Replication Complex, J. Mol. Biol., 304, 779, 10.1006/jmbi.2000.4266 · DOI
  144. Willmott, 1994, The Complex of DNA Gyrase and Quinolone Drugs with DNA Forms a Barrier to Transcription by RNA Polymerase, J. Mol. Biol., 242, 351, 10.1006/jmbi.1994.1586 · DOI
  145. Drolet, M. (2018). DNA Topoisomerases as Targets for Antibacterial Agents. DNA Topoisomerases: Methods and Protocols, Springer. · DOI
  146. Ashley, 2017, Activities of Gyrase and Topoisomerase IV on Positively Supercoiled DNA, Nucleic Acids Res., 45, 9611, 10.1093/nar/gkx649 · DOI
  147. Sugino, 1977, Mechanism of Action of Nalidixic Acid: Purification of Escherichia coli NalA Gene Product and Its Relationship to DNA Gyrase and a Novel Nicking-Closing Enzyme, Proc. Natl. Acad. Sci. USA, 74, 4767, 10.1073/pnas.74.11.4767 · DOI · Paper page
  148. Forterre, 2009, Phylogenomics of DNA Topoisomerases: Their Origin and Putative Roles in the Emergence of Modern Organisms, Nucleic Acids Res., 37, 679, 10.1093/nar/gkp032 · DOI · Paper page
  149. Colgan, 2018, Negative Supercoiling of DNA by Gyrase Is Inhibited in Salmonella enterica Serovar Typhimurium during Adaptation to Acid Stress, Mol. Microbiol., 107, 734, 10.1111/mmi.13911 · DOI
  150. Kreuzer, 1979, Escherichia coli Mutants Thermosensitive for Deoxyribonucleic Acid Gyrase Subunit A: Effects on Deoxyribonucleic Acid Replication, Transcription, and Bacteriophage Growth, J. Bacteriol., 140, 424, 10.1128/jb.140.2.424-435.1979 · DOI · Paper page
  151. Khodursky, 1995, Topoisomerase IV Is a Target of Quinolones in Escherichia coli, Proc. Natl. Acad. Sci. USA, 92, 11801, 10.1073/pnas.92.25.11801 · DOI · Paper page
  152. Gellert, 1977, Nalidixic Acid Resistance: A Second Genetic Character Involved in DNA Gyrase Activity, Proc. Natl. Acad. Sci. USA, 74, 4772, 10.1073/pnas.74.11.4772 · DOI · Paper page
  153. Hooper, 1998, Bacterial Topoisomerases, Anti-Topoisomerases, and Anti-Topoisomerase Resistance, Clin. Infect. Dis., 27, S54, 10.1086/514923 · DOI · Paper page
  154. 1996, ParC Subunit of DNA Topoisomerase IV of Streptococcus pneumoniae Is a Primary Target of Fluoroquinolones and Cooperates with DNA Gyrase A Subunit in Forming Resistance Phenotype, Antimicrob. Agents Chemother., 40, 2252, 10.1128/AAC.40.10.2252 · DOI · Paper page
  155. Pan, 1996, Involvement of Topoisomerase IV and DNA Gyrase as Ciprofloxacin Targets in Streptococcus pneumoniae, Antimicrob. Agents Chemother., 40, 2321, 10.1128/AAC.40.10.2321 · DOI · Paper page
  156. Fournier, 2000, Selective Targeting of Topoisomerase IV and DNA Gyrase in Staphylococcus aureus: Different Patterns of Quinolone- Induced Inhibition of DNA Synthesis, Antimicrob. Agents Chemother., 44, 2160, 10.1128/AAC.44.8.2160-2165.2000 · DOI
  157. Ince, 2002, Dual Targeting of DNA Gyrase and Topoisomerase IV: Target Interactions of Garenoxacin (BMS-284756, T-3811ME), a New Desfluoroquinolone, Antimicrob. Agents Chemother., 46, 3370, 10.1128/AAC.46.11.3370-3380.2002 · DOI · Paper page
  158. Nilius, 2003, In Vitro Antibacterial Potency and Spectrum of ABT-492, a New Fluoroquinolone, Antimicrob. Agents Chemother., 47, 3260, 10.1128/AAC.47.10.3260-3269.2003 · DOI
  159. Markham, 2017, Delafloxacin: First Global Approval, Drugs, 77, 1481, 10.1007/s40265-017-0790-5 · doi:10.1007/s40265-017-0790-5
  160. Cambau, 2009, Target Specificity of the New Fluoroquinolone Besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli, J. Antimicrob. Chemother., 63, 443, 10.1093/jac/dkn528 · doi:10.1093/jac/dkn528
  161. Pham, 2019, Quinolone Antibiotics, Med. Chem. Commun., 10, 1719, 10.1039/C9MD00120D · DOI · Paper page
  162. Rotschafer, J.C., Andes, D.R., and Rodvold, K.A. (2016). Pharmacodynamics of Fluoroquinolones. Antibiotic Pharmacodynamics, Springer. · doi:10.1007/978-1-4939-3323-5
  163. Cuprys, 2018, Fluoroquinolones Metal Complexation and Its Environmental Impacts, Coord. Chem. Rev., 376, 46, 10.1016/j.ccr.2018.05.019 · DOI
  164. Dougherty, T.J., and Pucci, M.J. (2012). Fluoroquinolone Resistance: Mechanisms, Restrictive Dosing, and Anti-Mutant Screening Strategies for New Compounds. Antibiotic Discovery and Development, Springer. · DOI · Paper page
  165. Mustaev, 2014, Fluoroquinolone-Gyrase-DNA Complexes, J. Biol. Chem., 289, 12300, 10.1074/jbc.M113.529164 · DOI · Paper page
  166. Wohlkonig, 2010, Structural Basis of Quinolone Inhibition of Type IIA Topoisomerases and Target-Mediated Resistance, Nat. Struct. Mol. Biol., 17, 1152, 10.1038/nsmb.1892 · DOI · Paper page
  167. Malik, 2016, Suppression of Gyrase-Mediated Resistance by C7 Aryl Fluoroquinolones, Nucleic Acids Res., 44, 3304, 10.1093/nar/gkw161 · DOI
  168. Marians, 1997, Mechanism of Quinolone Action: A drug-induced structural perturbation of the DNA precedes strand cleavage by Topoisomerase IV, J. Biol. Chem., 272, 9401, 10.1074/jbc.272.14.9401 · doi:10.1074/jbc.272.14.9401
  169. Kampranis, 1998, The DNA Gyrase-Quinolone Complex. ATP Hydrolysis and the Mechanism of DNA Cleavage, J. Biol. Chem., 273, 22615, 10.1074/jbc.273.35.22615 · doi:10.1074/jbc.273.35.22615
  170. Drlica, 2009, Quinolones: Action and Resistance Updated, Curr. Top. Med. Chem., 9, 981, 10.2174/156802609789630947 · DOI · Paper page
  171. Hiasa, 2000, DNA Gyrase-Mediated Wrapping of the DNA Strand Is Required for the Replication Fork Arrest by the DNA Gyrase-Quinolone-DNA Ternary Complex, J. Biol. Chem., 275, 34780, 10.1074/jbc.M001608200 · doi:10.1074/jbc.m001608200
  172. Anderson, 1999, Quinolones Inhibit DNA Religation Mediated by Staphylococcus aureus Topoisomerase IV: Changes in drug mechanism across evolutionary boundaries, J. Biol. Chem., 274, 35927, 10.1074/jbc.274.50.35927 · DOI
  173. Laponogov, 2009, Structural Insight into the Quinolone-DNA Cleavage Complex of Type IIA Topoisomerases, Nat. Struct. Mol. Biol., 16, 667, 10.1038/nsmb.1604 · DOI · Paper page
  174. Chen, 1996, DNA Gyrase and Topoisomerase IV on the Bacterial Chromosome: Quinolone-Induced DNA Cleavage, J. Mol. Biol., 258, 627, 10.1006/jmbi.1996.0274 · doi:10.1006/jmbi.1996.0274
  175. Drlica, 2008, Quinolone-Mediated Bacterial Death, Antimicrob. Agents Chemother., 52, 385, 10.1128/AAC.01617-06 · DOI · Paper page
  176. Malik, 2007, Effect of Anaerobic Growth on Quinolone Lethality with Escherichia coli, Antimicrob. Agents Chemother., 51, 28, 10.1128/AAC.00739-06 · DOI
  177. Hong, 2019, Post-Stress Bacterial Cell Death Mediated by Reactive Oxygen Species, Proc. Natl. Acad. Sci. USA, 116, 10064, 10.1073/pnas.1901730116 · DOI · Paper page
  178. Baquero, 2021, Proximate and Ultimate Causes of the Bactericidal Action of Antibiotics, Nat. Rev. Microbiol., 19, 123, 10.1038/s41579-020-00443-1 · DOI · Paper page
  179. Luan, 2018, Suppression of Reactive Oxygen Species Accumulation Accounts for Paradoxical Bacterial Survival at High Quinolone Concentration, Antimicrob. Agents Chemother., 62, e01622-17, 10.1128/AAC.01622-17 · DOI
  180. Bhatnagar, K., and Wong, A. (2019). The Mutational Landscape of Quinolone Resistance in Escherichia coli. PLoS ONE, 14. · DOI
  181. Baker, 2013, Fitness Benefits in Fluoroquinolone-Resistant Salmonella Typhi in the Absence of Antimicrobial Pressure, eLife, 2, e01229, 10.7554/eLife.01229 · DOI
  182. Castro, 2020, The Genetic Background Modulates the Evolution of Fluoroquinolone-Resistance in Mycobacterium tuberculosis, Mol. Biol. Evol., 37, 195, 10.1093/molbev/msz214 · DOI
  183. Vergalli, 2020, Porins and Small-Molecule Translocation across the Outer Membrane of Gram-Negative Bacteria, Nat. Rev. Microbiol., 18, 164, 10.1038/s41579-019-0294-2 · DOI · Paper page
  184. Sousa, 2017, The Binding of Free and Copper-Complexed Fluoroquinolones to OmpF Porins: An Experimental and Molecular Docking Study, RSC Adv., 7, 10009, 10.1039/C6RA26466B · DOI
  185. Ferreira, 2015, Ciprofloxacin Metalloantibiotic: An Effective Antibiotic with an Influx Route Strongly Dependent on Lipid Interaction?, J. Membr. Biol., 248, 125, 10.1007/s00232-014-9749-6 · DOI
  186. Toro, 1990, Clinical Isolate of a Porinless Salmonella Typhi Resistant to High Levels of Chloramphenicol, Antimicrob. Agents Chemother., 34, 1715, 10.1128/AAC.34.9.1715 · DOI
  187. Karczmarczyk, 2011, Mechanisms of Fluoroquinolone Resistance in Escherichia coli Isolates from Food-Producing Animals, Appl. Environ. Microbiol., 77, 7113, 10.1128/AEM.00600-11 · DOI
  188. Rushdy, 2013, Contribution of Different Mechanisms to the Resistance to Fluoroquinolones in Clinical Isolates of Salmonella enterica, Braz. J. Infect. Dis., 17, 431, 10.1016/j.bjid.2012.11.012 · doi:10.1016/j.bjid.2012.11.012
  189. Mathur, 2016, Attenuation of in Vitro Host–Pathogen Interactions in Quinolone-Resistant Salmonella Typhi Mutants, J. Antimicrob. Chemother., 71, 111, 10.1093/jac/dkv299 · DOI
  190. Xie, 2016, RpoE Is a Putative Antibiotic Resistance Regulator of Salmonella enteric Serovar Typhi, Curr. Microbiol., 72, 457, 10.1007/s00284-015-0983-7 · DOI
  191. Vidovic, 2019, Molecular and Physiological Characterization of Fluoroquinolone-Highly Resistant Salmonella Enteritidis Strains, Front. Microbiol., 10, 729, 10.3389/fmicb.2019.00729 · doi:10.3389/fmicb.2019.00729
  192. Du, 2018, Multidrug Efflux Pumps: Structure, Function and Regulation, Nat. Rev. Microbiol., 16, 523, 10.1038/s41579-018-0048-6 · DOI · Paper page
  193. Attia, 2020, Fluoroquinolone Resistance Conferred by GyrA, ParC Mutations, and AbaQ Efflux Pump among Acinetobacter baumannii Clinical Isolates Causing Ventilator-Associated Pneumonia, Acta Microbiol. Immunol. Hung., 67, 234, 10.1556/030.66.2019.040 · DOI
  194. 2019, Mechanisms of Action and of Resistance to Quinolones, Antibiot. Drug Resist., 1, 39
  195. Martin, 2010, Constitutive SoxS Expression in a Fluoroquinolone-Resistant Strain with a Truncated SoxR Protein and Identification of a New Member of the MarA-SoxS-Rob Regulon, MdtG, Antimicrob. Agents Chemother., 54, 1218, 10.1128/AAC.00944-09 · DOI
  196. Oethinger, 1998, Overexpression of the MarA or SoxS Regulatory Gene in Clinical Topoisomerase Mutants of Escherichia coli, Antimicrob. Agents Chemother., 42, 2089, 10.1128/AAC.42.8.2089 · DOI · Paper page
  197. Sharma, 2017, The Multiple Antibiotic Resistance Operon of Enteric Bacteria Controls DNA Repair and Outer Membrane Integrity, Nat. Commun., 8, 1444, 10.1038/s41467-017-01405-7 · DOI
  198. Villagra, 2019, Cysteine Auxotrophy Drives Reduced Susceptibility to Quinolones and Paraquat by Inducing the Expression of Efflux-Pump Systems and Detoxifying Enzymes in S. Typhimurium, Biochem. Biophys. Res. Commun., 515, 339, 10.1016/j.bbrc.2019.05.122 · doi:10.1016/j.bbrc.2019.05.122
  199. Millanao, 2020, Inactivation of Glutamine Synthetase-Coding Gene GlnA Increases Susceptibility to Quinolones Through Increasing Outer Membrane Protein F in Salmonella enterica Serovar Typhi, Front. Microbiol., 11, 428, 10.3389/fmicb.2020.00428 · DOI
  200. Yeung, 2011, The Sensor Kinase CbrA Is a Global Regulator That Modulates Metabolism, Virulence, and Antibiotic Resistance in Pseudomonas Aeruginosa, J. Bacteriol., 193, 918, 10.1128/JB.00911-10 · DOI

200 of 305 shown

Cited by

See all 213

Metadata

Authors
Millanao, A. R., Mora, A. Y., Villagra, N. A., Bucarey, S. A., & Hidalgo, A. A.
Venue
Molecules
Publisher
MDPI AG
Published
2021-11-25
Volume
26
Issue
23
Pages
7153
ISSN
1420-3049 (ISSN-L)
OpenAlex
W3216313742
Cited by
213
References
4
FWCI
7.91
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.